Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Company News

Why dwarfism start-up Therachon picked Pfizer takeout over IPO

At the cusp of seeking a public listing, Therachon Holding chose $340M deal with Pfizer and the chance to spin out a new company

May 8, 2019 11:10 AM UTC

Rather than file for an IPO as it had been planning to do, Therachon has elected to take a buyout offer from Pfizer, handing the pharma a clinical program to treat achondroplasia. Pfizer will pay $340 million up front for the biotech; its shareholders are eligible for $470 million in milestones.

Seeded by Versant Ventures in 2014, Therachon Holding AG (Basel, Switzerland) raised $100 million across two venture rounds. In August 2018, Novo Holdings led a $60 million round Therachon described as a mezzanine funding; Pfizer Ventures also participated in that round...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Pfizer Inc.

Therachon AG